PHP18 Fast-Tracking Innovation: A Scorecard for The Fda’s Expedited Review Process  by Chambers, J et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A517
number of expedited approval programs. The objective of this study was to evalu-
ate these programs by examining whether drugs included in them have provided 
larger health gains than drugs excluded from them. Methods: We considered the 
FDA’s priority review, accelerated approval, and fast-track programs. We estimated 
health gains in terms of quality-adjusted life-years (QALYs) for drugs approved 
for the first time between 1999 and 2011, relative to treatments available at the 
time of their approval. We identified QALY estimates from published cost-utility 
analyses, and comparative effectiveness studies that estimated relative effec-
tiveness using QALYs. We excluded studies that compared drugs to placebo or 
no treatment when an alternative active treatment was available, and to be con-
servative we excluded estimates from studies supported by the pharmaceutical 
industry. We compared QALY gains for drugs included in the designation pro-
grams vs. drugs excluded from them using Mann Whitney U tests. Results: We 
identified QALY gain estimates for 102 drugs, representing approximately 40% 
of drugs approved between 1999 and 2011. We included 15 of 37 drugs approved 
through accelerated approval, 54 of 149 drugs approved through priority review, 
and 24 of 65 drugs approved through fast-track designation. Drugs in the prior-
ity review program had mean QALY gains of 0.35 vs. -0.02 for drugs excluded 
(p= 0.011). Drugs included in the accelerated approval program had mean QALY 
gains of 0.43 vs. 0.13 for drugs excluded (p= 0.039). Drugs included in the fast-track 
designation program had mean QALY gains of 0.34 vs. 0.12 for drugs excluded 
(p= 0.014). ConClusions: This study suggests that drugs included by FDA in accel-
erated review programs have larger clinical gains than drugs excluded from the 
programs.
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objeCtives: Adverse drug effects (ADE) and their subsequent injuries lead to 
increased health resources utilization in older populations. This study aimed to 
(i) evaluate the types of ADE-related hospitalizations, (ii) analyze the associ-
ated costs of hospitalizations and length of stay. Methods: A retrospective, 
single-center observational study was conducted at an academic medical 
center in Singapore. Records of hospitalizations with diagnoses related to ADEs 
between January 2006 and December 2013 were identified using the International 
Classification of Diseases, Ninth and Tenth Revision, Clinical Modification (ICD-9 
and 10) codes. Summary statistics were used to report patient demographics, 
diagnoses, costs of hospitalizations (Singapore dollars, SGD$) and length of hos-
pital stay (LOS) in days. Results: The analysis included a total of 3088 patients 
aged ≥ 65 years old. The median age was 75 (IQR, 71-81) and majority were female 
(59.1%). The median cost of hospitalizations was $1014.65 (IQR, $607.65- $2003.40) 
and the median length of stay was 4 days (IQR, 2-8). The top five causative drug 
classes for ADE-related hospitalizations were diuretics (31.3%), anticoagulants 
(21.3%), anti-hypertensive (11.6%), anti-infective (5.6%) and anti-neoplastic (4.8%). 
Multivariate linear regression showed that anti-infectives are associated with 
longer LOS and higher total bills compared to the other four ADE-related admis-
sions i.e., 4.8 days longer (p< 0.001) and SGD$3734.90 more in cost (p< 0.001). This 
could be due to the various therapeutic monitoring parameters associated with 
anti-infective use, and a switch of therapy to more expensive alternatives should 
antibiotic resistance occur. ConClusions: ADE-related hospitalizations caused 
significant expenditure and morbidity in older population. Further efforts are nec-
essary to improve pharmacotherapy and relieve health care payers of preventable 
treatment costs. Multiple measures to prevent ADE-related hospitalizations such 
as electronic alerts, improving incidence reporting system, involving pharmacists 
to aid in prescribing decision and improving nursing administration of medica-
tions may potentially address this issue.
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objeCtives: Advanced therapy medicinal products (ATMPs) are innovative thera-
pies that encompass gene therapy, somatic cell therapy, and tissue engineered prod-
ucts. These therapies are expected to bring important health benefits, but also to 
substantially impact the pharmaceuticals budget. The aim of this study was to 
characterize ATMPs in development and discuss future implications in terms of 
market access. Methods: Clinical trials were searched in EUdraCT, clinicaltrials.
gov and ICTRP databases. Trials were classified by category of ATMPs as defined 
by European regulation EC N° 1394/2007, as well as by development phase and 
therapeutic area. Results: 939 clinical trials investigating ATMPs were identified 
(85% ongoing, 15% completed). Majority of trials were in early stages (phase I, I/II, 
II: 92%; phase II/III, III: 8%). Per category of ATMPs, we identified 53.6% of trials for 
somatic cell therapies, 22.8% for tissue engineered products, 22.4% for gene thera-
pies, and 1.2% for combined products (incorporating medical device). Therapeutic 
areas included cancer (24.8%), cardiovascular and blood diseases (21.5%), muscu-
loskeletal disorders (10.5%), immune system and inflammation (9.4%), neurology 
(9.1%) and others. 47.2% of trials enrolled less than 25 patients. Due to complexity 
and specificity of ATMPs, new clinical trial methodologies are being considered (e.g. 
small sample size, non-randomised trials, single arm trials, surrogate endpoints, 
integrated protocols, and adaptive designs). Evidence generation post-launch will 
become unavoidable to address payers’ expectations. ConClusions: ATMPs rep-
resent a fast growing field of interest. Although most of the products are in early 
development phase, the combined trial phase and the potential to cure severe 
chronic conditions suggest that ATMPs may reach the market earlier than stand-
ard therapies. Targeted therapies opened up the way for new trial methodologies, 
as well as the influence of patient copayments on the market shares of patented 
medications. Methods: We used data about on-patent volume, patient additional 
copayment, total pharmaceutical expenditure, and expenditure for on-patent medi-
cines. Data for expenditure were approached by sales. The database was derived 
from the Greek National Organization for Medicines (EOF), and Greece’s main health 
insurance fund (EOPYY). The data were selected on the basis of the therapeutic 
categories that include active substances under patent protection. Our empirical 
investigation was based on a linear regression, an exponential form equation, and a 
quadratic regression. Results: Our analysis suggests that pharmaceutical spend-
ing is significantly and positively associated with the volume of on-patent medi-
cines. According to the second regression analysis, patient additional copayment 
is positively related to spending for on-patent medicines. The relationship between 
the cumulative penetration of on-patent medicines and the share of the relevant 
expenditure on the total pharmaceutical expenditure was found positive and statisti-
cally significant. ConClusions: According to our empirical findings, the increasing 
penetration of on-patent medicines during 2001-2014 contributed significantly to 
the pharmaceutical spending increase, while the increase of spending for on-patent 
medicines increases the average additional copayment. However, further research 
regarding the extent to which the health effects of these medicines outweigh the high 
cost is essential for taking evidence-based reimbursement decisions.
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objeCtives: Biotechnology drugs (BD) help extending lives, slowing and prevent-
ing disease progression, combating debilitating and rare diseases, reducing hos-
pitalization, and improving quality of life. However, at the same time they assert 
greater burden on the public finances with their high prices. This study analyzes 
how spending on BD evolved in Turkey, then shows how much it contributed on 
the growth of the total budget, and finally suggests policies maintaining future 
sustainability. Methods: Claims data from Turkish Social Security Institution 
(SGK) for all ambulatory care drugs reimbursed were collected in the period of 
January 2007 to December 2014 and drugs defined as BD were decided among all 
reimbursed drugs. Spending on BD, their share on overall budget, and distribu-
tion of BD in terms of ATC classification were all computed. Results: Number 
of BD reimbursed by SGK in 2014 reached to 202 from 107 in 2007, meaning that 
on average 14 new drugs were added to the reimbursement list yearly. While BD 
only represented 7.2% of the total public drug spending in 2007, the figure skyrock-
eted to 17.4% in 2014. Average annual growth rate for BD spending and aggregate 
spending were 23% and 8% respectively. In addition, between 2007 and 2014 total 
amount paid to BD hiked by 316%, but overall budget went up only 73% in the 
same period. ATC-L (Antineoplastic and immunomodulating agents) received the 
largest share (52%) from bio-spending, followed by ATC-A (alimentary tract and 
metabolism), and ATC-B (blood and blood forming organs), all three constituting 
nearly 90%. ConClusions: There has been an increasing trend in BD spending 
in Turkey, threating the sustainability of drug budget. Hence introducing new 
policies is of great importance. Leaving a larger room for those drugs, considering 
value-based pricing, and developing risk sharing agreements can be listed as the 
main policy recommendations for Turkey.
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objeCtives: Adverse drug events (ADE) have a considerable adverse impact on 
human health, and have been associated with increased healthcare costs. Several 
studies addressed the economic burden of drug-related morbidity, but, to date, 
no attempt has been made to estimate the average costs of ADE. The aim of this 
systematic review is to estimate costs related with ADE. Methods: MEDLINE and 
Cochrane Library were searched from 1995 up to 2015. Experimental and obser-
vational studies, economic evaluations and systematic reviews were included. 
Methodological quality of selected studies was assessed by Cochrane Collaboration 
tool for experimental and observational studies, Evers Checklist for economic evalu-
ations and PRISMA guideline for systematic reviews. Studies were classified accord-
ing to the setting analyzed in “Ambulatory”, and “Hospital”. Costs were classified as 
“Direct” and “Indirect”. Data were analyzed using descriptive statistics. Results: 
Forty-one (82%) observational studies, 5 (10%) economic evaluations and 4 (18%) 
systematic reviews were included. Economic evaluations were the type of study 
assessed with the highest methodological quality score. The mean study duration 
was 29 months [2 weeks–127 months]. Most of the studies assessed the median 
costs of any ADE (n= 30; 60%). Thirty-three (66%) studies evaluated any therapeutic 
group. Thirty-two (64%) studies estimated costs of ADE in “Hospital” setting. “Direct 
medical costs” were the most frequently type of costs evaluated (n= 26; 84%). The 
unit of measure and the way how the costs were estimated varied widely across the 
studies. ConClusions: Several studies have investigated the costs related with 
ADE. However, due to the wide variety of study methodology, settings analyzed, and 
type and unit of measurement of costs evaluated, no conclusions can be drawn. 
Further work is warranted to standardize this type of study in order to properly 
estimate the economic burden of ADE.
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objeCtives: The United States Food and Drug Administration (FDA) accelerates 
the review of drugs that show potential to treat serious conditions through a 
